BIOLIGO announced that it has received RMB 300 million in its series A round of funding led by Carlyle Beijing Partners Fund II, L.P., a fund managed by The Carlyle Group Inc. on October 22, 2021. The transaction also included participation from CICC Qide Innovative Biopharmaceutical Equity Investment Fund, a fund managed by CICC Investment Group Company Limited and Yuan-sheng Suzhou Industrial Park Venture Capital Management Co., Ltd.